"Drug development based on herbal cannabinoids has been slow in the U.S. largely because of the scheduling issue and reluctance of the National Institute on Drug Abuse to approve research studies. A great deal of the current dispensary-based knowledge about the uses and efficacies of various strains has been the product of popular trial and error, a potentially dangerous and irreproducible way to approach science."
That's a quote from Anne Wallace, writing in MJ Investor News. I'll let you consider the implications without further ado.
Comments
Post a Comment